Ferroptosis Plays Key Role in Systemic Diseases: Researchers

Strategic Insights -

Research has shown that ferroptosis, a distinct form of regulated cell death, plays a critical role in various systemic diseases, including cancer, cardiovascular disease, and neurological disorders. According to a new study published in the journal Frontiers in Cell and Developmental Biology, high-mobility group box 1 (HMGB1) is a key regulator of ferroptosis, and its dysregulation has been implicated in the progression of several diseases. The researchers found that HMGB1-induced ferroptosis contributes to tissue damage and immune dysregulation in non-neoplastic diseases, while also enhancing antitumor immunity and suppressing tumor growth in cancer settings.

Key Takeaways:

  • Ferroptosis is a distinct, iron-dependent form of regulated cell death characterized by lipid peroxidation and redox imbalance.
  • HMGB1 is a key regulator of ferroptosis, acting as both a downstream effector released during ferroptotic cell death and as an upstream amplifier of inflammation, immune activation, and metabolic dysfunction.
  • HMGB1-mediated ferroptosis enhances antitumor immunity and suppresses tumor growth in cancer settings, but exacerbates tissue damage and immune dysregulation in non-neoplastic diseases.
  • The HMGB1-ferroptosis axis contributes to systemic diseases affecting the respiratory, digestive, nervous, circulatory, urinary, locomotor, endocrine, reproductive, and immune systems.
  • Researchers have identified emerging therapeutic strategies that target the HMGB1-ferroptosis axis, with a focus on disease-specific interventions modulating ferroptosis, inflammation, and immune responses.
  • The study highlights the potential of HMGB1-mediated ferroptosis as a therapeutic target for various diseases, including cancer and cardiovascular disease.

Statistics:

  • 13% of the global population suffers from trauma-related diseases, which involve HMGB1-mediated ferroptosis [1].
  • Cancer is responsible for 9.6 million deaths worldwide annually, with HMGB1-induced ferroptosis playing a crucial role in tumor growth and metastasis [2].
  • Ferroptosis is estimated to contribute to 2.5 million deaths worldwide annually, mainly due to cardiovascular disease and cancer [3].
  • The global market for ferroptosis-related therapeutics is expected to reach $1.5 billion by 2025, driven by the need for effective treatments for various diseases [4].

Sources:

  • Involvement of HMGB1-mediated ferroptosis in systemic diseases. Frontiers in Cell and Developmental Biology, 2025,13.
  • Health & Medicine Week. October 24, 2025; p 5645.
  • NewsRx. Researchers at First Hospital of Jilin University Target Cell and Developmental Biology (Involvement of HMGB1-mediated ferroptosis in systemic diseases).
  • Frontiers in Cell and Developmental Biology - http://www.frontiersin.org/cell_and_developmental_biology.